JP2009510068A5 - - Google Patents

Download PDF

Info

Publication number
JP2009510068A5
JP2009510068A5 JP2008533471A JP2008533471A JP2009510068A5 JP 2009510068 A5 JP2009510068 A5 JP 2009510068A5 JP 2008533471 A JP2008533471 A JP 2008533471A JP 2008533471 A JP2008533471 A JP 2008533471A JP 2009510068 A5 JP2009510068 A5 JP 2009510068A5
Authority
JP
Japan
Prior art keywords
direct compression
tablet
active ingredient
granulation
melt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2008533471A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009510068A (ja
JP5415762B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2006/037198 external-priority patent/WO2007041053A2/en
Publication of JP2009510068A publication Critical patent/JP2009510068A/ja
Publication of JP2009510068A5 publication Critical patent/JP2009510068A5/ja
Application granted granted Critical
Publication of JP5415762B2 publication Critical patent/JP5415762B2/ja
Anticipated expiration legal-status Critical
Active legal-status Critical Current

Links

JP2008533471A 2005-09-29 2006-09-25 新規製剤 Active JP5415762B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US72262405P 2005-09-29 2005-09-29
US60/722,624 2005-09-29
PCT/US2006/037198 WO2007041053A2 (en) 2005-09-29 2006-09-25 Formulation comprising metformin and vildagli ptin

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013146163A Division JP2013241429A (ja) 2005-09-29 2013-07-12 新規製剤

Publications (3)

Publication Number Publication Date
JP2009510068A JP2009510068A (ja) 2009-03-12
JP2009510068A5 true JP2009510068A5 (cg-RX-API-DMAC10.html) 2009-11-05
JP5415762B2 JP5415762B2 (ja) 2014-02-12

Family

ID=37876819

Family Applications (9)

Application Number Title Priority Date Filing Date
JP2008533471A Active JP5415762B2 (ja) 2005-09-29 2006-09-25 新規製剤
JP2013146163A Withdrawn JP2013241429A (ja) 2005-09-29 2013-07-12 新規製剤
JP2015201008A Active JP6270793B2 (ja) 2005-09-29 2015-10-09 新規製剤
JP2017202104A Withdrawn JP2018052945A (ja) 2005-09-29 2017-10-18 新規製剤
JP2019042906A Withdrawn JP2019131567A (ja) 2005-09-29 2019-03-08 新規製剤
JP2020151616A Active JP7194153B2 (ja) 2005-09-29 2020-09-09 新規製剤
JP2022065829A Withdrawn JP2022106763A (ja) 2005-09-29 2022-04-12 新規製剤
JP2023193231A Pending JP2024028702A (ja) 2005-09-29 2023-11-13 新規製剤
JP2024123496A Withdrawn JP2024167195A (ja) 2005-09-29 2024-07-30 新規製剤

Family Applications After (8)

Application Number Title Priority Date Filing Date
JP2013146163A Withdrawn JP2013241429A (ja) 2005-09-29 2013-07-12 新規製剤
JP2015201008A Active JP6270793B2 (ja) 2005-09-29 2015-10-09 新規製剤
JP2017202104A Withdrawn JP2018052945A (ja) 2005-09-29 2017-10-18 新規製剤
JP2019042906A Withdrawn JP2019131567A (ja) 2005-09-29 2019-03-08 新規製剤
JP2020151616A Active JP7194153B2 (ja) 2005-09-29 2020-09-09 新規製剤
JP2022065829A Withdrawn JP2022106763A (ja) 2005-09-29 2022-04-12 新規製剤
JP2023193231A Pending JP2024028702A (ja) 2005-09-29 2023-11-13 新規製剤
JP2024123496A Withdrawn JP2024167195A (ja) 2005-09-29 2024-07-30 新規製剤

Country Status (31)

Country Link
US (4) US20080227825A1 (cg-RX-API-DMAC10.html)
EP (1) EP1948149B2 (cg-RX-API-DMAC10.html)
JP (9) JP5415762B2 (cg-RX-API-DMAC10.html)
KR (2) KR101595169B1 (cg-RX-API-DMAC10.html)
CN (1) CN101277688B (cg-RX-API-DMAC10.html)
AR (1) AR055441A1 (cg-RX-API-DMAC10.html)
AT (1) ATE533481T1 (cg-RX-API-DMAC10.html)
AU (1) AU2006297444B2 (cg-RX-API-DMAC10.html)
BR (1) BRPI0616694B8 (cg-RX-API-DMAC10.html)
CA (1) CA2623011C (cg-RX-API-DMAC10.html)
CY (1) CY1112305T1 (cg-RX-API-DMAC10.html)
DK (1) DK1948149T4 (cg-RX-API-DMAC10.html)
EC (1) ECSP088318A (cg-RX-API-DMAC10.html)
ES (1) ES2377572T5 (cg-RX-API-DMAC10.html)
GT (1) GT200600426A (cg-RX-API-DMAC10.html)
IL (1) IL189856A (cg-RX-API-DMAC10.html)
JO (2) JO3795B1 (cg-RX-API-DMAC10.html)
MA (1) MA29854B1 (cg-RX-API-DMAC10.html)
MY (1) MY144975A (cg-RX-API-DMAC10.html)
NO (2) NO346101B1 (cg-RX-API-DMAC10.html)
NZ (1) NZ566430A (cg-RX-API-DMAC10.html)
PE (1) PE20070583A1 (cg-RX-API-DMAC10.html)
PH (1) PH12014500051B1 (cg-RX-API-DMAC10.html)
PL (1) PL1948149T5 (cg-RX-API-DMAC10.html)
PT (1) PT1948149E (cg-RX-API-DMAC10.html)
SG (4) SG10201401826TA (cg-RX-API-DMAC10.html)
SI (1) SI1948149T2 (cg-RX-API-DMAC10.html)
TN (1) TNSN08146A1 (cg-RX-API-DMAC10.html)
TW (1) TWI389685B (cg-RX-API-DMAC10.html)
WO (1) WO2007041053A2 (cg-RX-API-DMAC10.html)
ZA (1) ZA200801773B (cg-RX-API-DMAC10.html)

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
NZ585116A (en) * 2005-05-10 2011-12-22 Novartis Ag Extrusion process for making compositions with poorly compressible therapeutic compounds e.g. metformin hydrochloride
US7772191B2 (en) 2005-05-10 2010-08-10 Boehringer Ingelheim International Gmbh Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
US20080227825A1 (en) * 2005-09-29 2008-09-18 Yatindra Joshi Formulation
WO2007078726A2 (en) * 2005-12-16 2007-07-12 Merck & Co., Inc. Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with metformin
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
BRPI0711558A2 (pt) 2006-05-04 2011-11-08 Boeringer Ingelheim Internat Gmbh polimorfos
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
PE20090938A1 (es) 2007-08-16 2009-08-08 Boehringer Ingelheim Int Composicion farmaceutica que comprende un derivado de benceno sustituido con glucopiranosilo
FR2928836B1 (fr) * 2008-03-21 2011-08-26 Servier Lab Forme galenique secable permettant une liberation modifiee du principe actif
PE20140960A1 (es) * 2008-04-03 2014-08-15 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
AU2014262269B2 (en) * 2008-04-03 2017-02-02 Boehringer Ingelheim International Gmbh DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation
BRPI0916997A2 (pt) 2008-08-06 2020-12-15 Boehringer Ingelheim International Gmbh Inibidor de dpp-4 e seu uso
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
AU2009290911A1 (en) 2008-09-10 2010-03-18 Boehringer Ingelheim International Gmbh Combination therapy for the treatment of diabetes and related conditions
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
KR101054911B1 (ko) 2008-10-17 2011-08-05 동아제약주식회사 디펩티딜펩티다아제-ⅳ의 활성을 저해하는 화합물 및 다른 항당뇨 또는 항비만 약물을 유효성분으로 함유하는 당뇨 또는 비만의 예방 및 치료용 약학적 조성물
GB2465796A (en) * 2008-12-01 2010-06-02 Bee Kang Tan Metformin for the therapeutic use of conditions with raised serum amyloid A levels
EP2382216A1 (en) 2008-12-23 2011-11-02 Boehringer Ingelheim International GmbH Salt forms of organic compound
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
MX339194B (es) 2009-02-13 2016-05-16 Boehringer Ingelheim Int Composicion farmaceutica que comprende un inhibidor de sglt2, un inhibidor de dpp-iv y opcionalmente otro agente antidiabetico, y usos de la misma.
KR20110118668A (ko) 2009-02-13 2011-10-31 베링거 인겔하임 인터내셔날 게엠베하 １형 당뇨병, ２형 당뇨병, 내당능 장애 또는 고혈당증을 치료하기 위한 ｓｇｌｔ­２ 억제제
EA034049B1 (ru) * 2009-07-31 2019-12-23 КРКА, д.д., НОВО МЕСТО Гранулят, включающий вилдаглиптин, способ его получения и фармацевтическая композиция
EP2295083A1 (de) 2009-09-15 2011-03-16 Ratiopharm GmbH Pharmazeutische Zusammensetzung mit den Wirkstoffen Metformin und Sitagliptin oder Vildagliptin
DK2486029T3 (en) 2009-09-30 2015-08-24 Boehringer Ingelheim Int Methods of making of glucopyranosyl-substituted benzyl-benzene derivatives.
US10610489B2 (en) 2009-10-02 2020-04-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof
CN107028924A (zh) * 2009-10-02 2017-08-11 勃林格殷格翰国际有限公司 包含bi‑1356和二甲双胍的药物组合物
WO2011049773A1 (en) * 2009-10-23 2011-04-28 Merck Sharp & Dohme Corp. Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with pioglitazone
EA034869B1 (ru) 2009-11-27 2020-03-31 Бёрингер Ингельхайм Интернациональ Гмбх Лечение генотипированных пациентов с диабетом ингибиторами дпп-4, такими как линаглиптин
CA2784996A1 (en) * 2009-12-22 2011-06-30 Novartis Ag Formulation comprising 1 h-quinazoline-2,4-dione ampa receptor antagonists, in the form of immediate release tablets and preparation thereof
MX341025B (es) 2010-05-05 2016-08-04 Boehringer Ingelheim Int Gmbh * Terapia de combinacion.
PH12012502524A1 (en) 2010-06-24 2014-02-10 Boehringer Ingelheim Int Diabetes therapy
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
TR201010683A1 (tr) * 2010-12-21 2012-07-23 Sanovel İlaç San. Ve Ti̇c. A.Ş. Vildagliptin formülasyonları.
AR085689A1 (es) 2011-03-07 2013-10-23 Boehringer Ingelheim Int Composiciones farmaceuticas de metformina, linagliptina y un inhibidor de sglt-2
EP3517539B1 (en) 2011-07-15 2022-12-14 Boehringer Ingelheim International GmbH Substituted dimeric quinazoline derivative, its preparation and its use in pharmaceutical compositions for the treatment of type i and ii diabetes
EP2753328A1 (en) * 2011-09-07 2014-07-16 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Dpp-iv inhibitor formulations
WO2013077824A1 (en) * 2011-11-23 2013-05-30 Mahmut Bilgic Preparation process for a formulation comprising metformin
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
US9192617B2 (en) 2012-03-20 2015-11-24 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
US20130303554A1 (en) 2012-05-14 2013-11-14 Boehringer Ingelheim International Gmbh Use of a dpp-4 inhibitor in sirs and/or sepsis
JP6224084B2 (ja) 2012-05-14 2017-11-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 糸球体上皮細胞関連障害及び／又はネフローゼ症候群の治療に用いるｄｐｐ−４阻害薬としてのキサンチン誘導体
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
WO2014102715A1 (en) 2012-12-24 2014-07-03 Ranbaxy Laboratories Limited Pharmaceutical compositions comprising a biguanide and a low dose antidiabetic agent
MX2015008427A (es) * 2012-12-27 2015-10-22 Zentiva Saglik Ürünleri San Ve Tic A S Proceso de granulacion en seco para producir composiciones de comprimidos de metformina y sus composiciones.
HRP20190101T1 (hr) 2013-04-05 2019-03-08 Boehringer Ingelheim International Gmbh Terapeutske uporabe empagliflozina
CA2812519A1 (en) 2013-04-05 2014-10-05 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
US20140303097A1 (en) 2013-04-05 2014-10-09 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
US11813275B2 (en) 2013-04-05 2023-11-14 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
PL2986304T3 (pl) 2013-04-18 2022-05-02 Boehringer Ingelheim International Gmbh Kompozycja farmaceutyczna, sposoby leczenia i jej zastosowania
WO2014184742A1 (en) 2013-05-13 2014-11-20 Ranbaxy Laboratories Limited Pharmaceutical compositions containing a biguanide and a low dose antidiabetic agent
JP5922310B2 (ja) * 2013-07-25 2016-05-24 株式会社三和化学研究所 医薬製剤
CN104546779A (zh) * 2013-10-14 2015-04-29 深圳海王药业有限公司 高药物荷载的枸橼酸西地那非片剂及其制备方法
EA032126B1 (ru) * 2013-12-23 2019-04-30 Крка, Д.Д. Ново Место Твердая фармацевтическая композиция, содержащая метформин и вилдаглиптин, и способы ее получения
CN103735544B (zh) * 2014-02-14 2015-08-19 南京华威医药科技开发有限公司 一种维达列汀/盐酸二甲双胍复方制剂的制备工艺
US9526728B2 (en) 2014-02-28 2016-12-27 Boehringer Ingelheim International Gmbh Medical use of a DPP-4 inhibitor
CN103845326B (zh) * 2014-03-24 2017-07-07 江苏奥赛康药业股份有限公司 维格列汀与二甲双胍的复方组合物及其制备方法
CN105582008A (zh) * 2014-11-14 2016-05-18 北京赛林泰医药技术有限公司 一种含有维格列汀和二甲双胍的组合物及其制备方法
KR102496851B1 (ko) * 2015-04-10 2023-02-08 제이더블유중외제약 주식회사 아나글립틴 또는 이의 약학적으로 허용 가능한 염 및 메트포르민 또는 이의 약학적으로 허용 가능한 염을 포함하는 약제학적 조성물 및 그의 제조 방법
WO2017060861A2 (en) * 2015-10-07 2017-04-13 Steerlife India Private Limited Rapidly disintegrating tablet compositions of dpp-iv inhibitors with low mineral content
CN105769796B (zh) * 2016-05-04 2019-06-04 杭州百诚医药科技股份有限公司 一种含有维格列汀和盐酸二甲双胍的药物制剂及其制备方法
CN109310697A (zh) 2016-06-10 2019-02-05 勃林格殷格翰国际有限公司 利格列汀和二甲双胍的组合
CN106432026A (zh) * 2016-09-12 2017-02-22 重庆医科大学 一类对糖尿病具有潜在治疗活性的化合物
CN106421794A (zh) * 2016-09-27 2017-02-22 黑龙江珍宝岛药业股份有限公司 一种用于治疗ⅱ型糖尿病的药物组合物及其制备方法
WO2018087132A1 (en) 2016-11-10 2018-05-17 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
TW201938147A (zh) * 2017-12-18 2019-10-01 德商拜耳廠股份有限公司 阿卡波糖與甲福明之固定劑量組合錠劑配製物及其製法
TR201722603A2 (tr) * 2017-12-28 2019-07-22 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Metformi̇n ve si̇tagli̇pti̇n i̇çeren sicak eri̇tme ekstrüzyonu i̇le gerçekleşti̇ri̇len tablet formülasyonlari
KR102622198B1 (ko) * 2018-03-30 2024-01-09 한미약품 주식회사 빌다글립틴을 함유하는 경구용 고형제제 및 그의 제조 방법
EP3793529A1 (en) 2018-05-18 2021-03-24 Galenicum Health S.L.U. Stable pharmaceutical compositions of dpp-iv inhibitors in combination with metformin in the form of immediate release tablets
KR102647472B1 (ko) * 2018-07-31 2024-03-14 한미약품 주식회사 디펩티딜 펩티다아제-4 억제제 및 메트포르민을 포함하는 경구용 고형 복합제제 및 이의 제조방법
GR1009644B (el) * 2018-09-25 2019-11-12 Φαρματεν Α.Β.Ε.Ε. Φαρμακευτικο σκευασμα που περιλαμβανει βιλνταγλιπτινη και μετφορμινη και μεθοδος για την παρασκευη αυτου
RU2712097C1 (ru) * 2018-09-28 2020-01-24 Общество с ограниченной ответственностью "Необиотек" Ингибитор дипептидилпептидазы-4 для лечения сахарного диабета 2-го типа, соединения (варианты)
WO2020098904A1 (en) 2018-11-12 2020-05-22 Pharmaceutical Oriented Services Ltd Dosage form containing metformin and a dipeptidyl peptidase iv inhibitor
CN113905738A (zh) * 2019-03-25 2022-01-07 乔治全球健康研究院 低剂量三联组合制剂
KR102693304B1 (ko) * 2019-04-16 2024-08-08 한미약품 주식회사 빌다글립틴 염산염 함유 복합 제제의 안정성 개선을 위한 포장재
TR201913472A2 (tr) 2019-09-06 2021-03-22 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Vi̇ldagli̇pti̇n ve metformi̇n i̇çeren bi̇r kombi̇nasyon
EP4045520A1 (en) 2019-10-16 2022-08-24 Bayer Aktiengesellschaft Methods for the improved formation of acarbose
KR102362342B1 (ko) * 2020-01-31 2022-02-14 주식회사 경보제약 빌다글립틴 및 메트포민 포함하는 복합 정제
KR102856843B1 (ko) * 2020-03-30 2025-09-08 한미약품 주식회사 시타글립틴, 다파글리플로진, 및 메트포르민을 포함하는 경구용 복합정제
TR202009949A1 (tr) * 2020-06-25 2022-01-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Vi̇ldagli̇pti̇n ve metformi̇n hci i̇çeren bi̇r fi̇lm kapli tablet
WO2022070209A1 (en) * 2020-09-29 2022-04-07 Dr. Reddy's Laboratories Limited Biphasic release fixed dose combination formulations
CN114306267A (zh) * 2020-09-30 2022-04-12 深圳翰宇药业股份有限公司 一种西格列汀二甲双胍片制剂及其制备方法
GB2599950A (en) * 2020-10-16 2022-04-20 Zentiva Ks Pharmaceutical compositions with low amounts of nitrosamine impurities and methods for producing the same
JP2022151564A (ja) * 2021-03-26 2022-10-07 東和薬品株式会社 薬効成分としてビルダグリプチンおよびメトホルミンを含む錠剤
WO2022211762A1 (en) 2021-03-29 2022-10-06 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi The film coated tablet of vildagliptin and metformin hydrochloride
JP2022182181A (ja) * 2021-05-27 2022-12-08 キョーリンリメディオ株式会社 ビルダグリプチン含有医薬品

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3174901A (en) * 1963-01-31 1965-03-23 Jan Marcel Didier Aron Samuel Process for the oral treatment of diabetes
US3621097A (en) * 1970-03-30 1971-11-16 Jan Marcel Didier Aron Samuel Method and compositions for treatment of mental illness
DE3720757A1 (de) * 1987-06-24 1989-01-05 Bayer Ag Dhp-manteltablette
IT1276130B1 (it) * 1995-11-14 1997-10-27 Gentili Ist Spa Associazione glibenclamide-metformina, composizioni farmaceutiche che la contengono e loro uso nel trattamento del diabete mellito di tipo
DE19823831A1 (de) * 1998-05-28 1999-12-02 Probiodrug Ges Fuer Arzneim Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen
CO5150173A1 (es) * 1998-12-10 2002-04-29 Novartis Ag Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv
ATE385421T1 (de) * 2000-01-21 2008-02-15 Novartis Pharma Gmbh Zusammensetzungen bestehend aus dipeptidylpeptidase-iv inhibitoren und antidiabetica
US7510728B2 (en) * 2000-10-06 2009-03-31 Takeda Pharmaceutical Company Limited Solid preparations
JP4848558B2 (ja) * 2001-05-08 2011-12-28 トーアエイヨー株式会社 塩酸メトホルミン含有速放性錠剤
FR2824825B1 (fr) * 2001-05-15 2005-05-06 Servier Lab Nouveaux derives d'alpha-amino-acides, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
CN1805738A (zh) * 2003-06-16 2006-07-19 兰贝克赛实验室有限公司 持续释放的二甲双胍片剂
JP5122144B2 (ja) * 2004-01-20 2013-01-16 ノバルティス アーゲー 直接圧縮製剤および方法
EP1807066A1 (en) * 2004-10-25 2007-07-18 Novartis AG Combination of dpp-iv inhibitor, ppar antidiabetic and metformin
GT200600008A (es) * 2005-01-18 2006-08-09 Formulacion de compresion directa y proceso
GT200600218A (es) * 2005-06-10 2007-03-28 Formulación y proceso de compresión directa
US20080227825A1 (en) * 2005-09-29 2008-09-18 Yatindra Joshi Formulation

Similar Documents

Publication Publication Date Title
CN103096881B (zh) 含有具有不愉快味道的药物的膜制剂
CN103550165B (zh) 一种含有利伐沙班的药物组合物及其制备方法
EP3120871B1 (en) Solid dispersion
ES2768349T3 (es) Preparación farmacéutica que comprende un derivado de fenilalanina
JP2005524658A5 (cg-RX-API-DMAC10.html)
EP2893940A2 (en) Granulated material for tablet that rapidly disintegrates in mouth
ES2435943T3 (es) Formulaciones de vildagliptina
CN104055743B (zh) 一种含利伐沙班口服制剂的制备方法
EP2207534B1 (en) Mechanical protective layer for solid dosage forms
EP3165219A1 (en) Allisartan isoproxil solid dispersion and pharmaceutical composition comprising same
CA2797042A1 (en) Fingolimod in the form of a solid solution
CN104739809B (zh) 能提供高载药量的水不溶性药物的膜剂及其制备方法
CN104887633A (zh) 一种利伐沙班片剂及其制备方法
CA2566931A1 (en) Tablets exhibiting reduced drug release variability
CN102137664B (zh) 具有被边界隔开的有效成分的固体药物制剂
CN105267150A (zh) 一种利伐沙班固体组合物的制备方法
CN101854921A (zh) 用于口服施用ppi的药物制剂
CN106074420B (zh) 一种高生物利用度的水飞蓟宾葡甲胺片的制备方法
JPH0797325A (ja) 安定な固形製剤およびその製造法
JP6805699B2 (ja) 医薬組成物、医薬組成物の製造方法、及び非晶質体の安定性を向上させる方法
ES2313578T3 (es) Formulacion estable que comprende una combinacion de un farmaco sensible a la humedad y un segundo farmaco y procedimiento de preparacion de la misma.
ES2377473B1 (es) Pellets entéricos de duloxetina.
CN102743384A (zh) 一种含有西他沙星的药物组合物
US20150238615A1 (en) Denaturants for sympathomimetic amines
CN103585185A (zh) 香菇提取物缓释微丸及其制备方法